Fatigue in cancer patients receiving chemotherapy: an analysis of published studies.
暂无分享,去创建一个
A. Iop | A Iop | A M Manfredi | S Bonura | S. Bonura | A. Manfredi
[1] K. Dalhoff,et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. , 2001, European journal of cancer.
[2] B. Scheithauer,et al. A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas , 2000, Investigational New Drugs.
[3] M. Gore,et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[5] M. Kris,et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Greil,et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Friedlander,et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Hainsworth,et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Pignon,et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Jacobsen,et al. Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? , 1999, Cancer control : journal of the Moffitt Cancer Center.
[11] S. Barni,et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] E. Frei,et al. Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU). , 1974, Annals of surgery.
[13] P. Jacobsen,et al. A multidimensional measure of fatigue for use with cancer patients. , 1998, Cancer practice.
[14] M. Dodd,et al. Patients' perspectives of fatigue while undergoing chemotherapy. , 1997, Oncology nursing forum.
[15] M. Mori,et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. , 2001, Medicine and science in sports and exercise.
[16] John A Thompson,et al. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. , 2002, Oncology nursing forum.
[17] D. Cella,et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. , 1997, Seminars in hematology.
[18] N. Malamos,et al. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. , 2001, European journal of cancer.
[19] R. Schilsky,et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] J. Muir,et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Richardson,et al. Fatigue: a concept analysis. , 1996, International Journal of Nursing Studies.
[22] B N Bundy,et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Shin,et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Aistars. Fatigue in the cancer patient: a conceptual approach to a clinical problem. , 1987, Oncology nursing forum.
[25] S. Closs,et al. Side effects expected and experienced by women receiving chemotherapy for breast cancer. , 1991, BMJ.
[26] D. Nerenz,et al. Factors contributing to emotional distress during cancer chemotherapy , 1982, Cancer.
[27] Kathleen M. Fairfield,et al. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. , 1998, Archives of internal medicine.
[28] J. Hainsworth,et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Schilsky,et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Rossi,et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. , 1997, European journal of cancer.
[31] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] K. Friedrichs,et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Winningham. Walking program for people with cancer. Getting started. , 1991, Cancer nursing.
[35] F. Dimeo,et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy , 1999, Cancer.
[36] J. Groopman,et al. Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.
[37] S. Pickard-Holley. Fatigue in cancer patients: A descriptive study , 1991, Cancer nursing.
[38] I. Vlachonikolis,et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.
[39] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Ducreux,et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] V. Mock. Fatigue management , 2001, Cancer.
[42] H. Keizer,et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] L. Nail,et al. Fatigue and the cancer experience: the state of the knowledge. , 1994, Oncology nursing forum.
[44] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] J. Bogaerts,et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Daniel G Haller,et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] L. Hutchins,et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] R. Rosso,et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] K. Blesch,et al. Correlates of fatigue in people with breast or lung cancer. , 1991, Oncology nursing forum.
[50] J. Crowley,et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Hainsworth,et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma , 2002 .
[52] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[53] S. Horning,et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. , 2000, The oncologist.
[54] E. Smets,et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. , 1995, Journal of psychosomatic research.
[55] Mellar P. Davis,et al. Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study , 2001, The American journal of hospice & palliative care.
[56] L. Fallowfield,et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy , 2002, British Journal of Cancer.
[57] A Gordon,et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Nixon,et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Gregor,et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] H. Burger,et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] S. Barni,et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] J. Nortier,et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] R. Ozols,et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] S. Lippman,et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma , 2001, Cancer.
[65] Cancer-related fatigue: guidelines for evaluation and management. , 1999 .
[66] G. Batist,et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] M. Zucchetti,et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] S. Cha,et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] D. Cella,et al. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.
[70] Terry L. Smith,et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] J. Kugler,et al. Phase II trials of 5‐fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma , 1996, Cancer.
[72] J. Glaspy. Anemia and fatigue in cancer patients , 2001, Cancer.
[73] C. Cleeland,et al. The rapid assessment of fatigue severity in cancer patients , 1999, Cancer.